Core Insights - The Beijing Stock Exchange (BSE) is becoming a significant platform for innovative small and medium-sized enterprises, with 290 listed companies and a total market capitalization nearing 1 trillion yuan as of January 23, 2026 [1][4] Group 1: Recent Listings - Three companies have recently gone public on the BSE: Kema Materials, Aisheren, and Guoliang New Materials, all of which have shown strong stock performance post-listing [2][3] - Kema Materials, specializing in dry and wet friction plates, saw its stock price surge by 371.27% on its first trading day, closing at 54.95 yuan per share [2] - Aisheren, focused on medical health products, experienced a 175.59% increase in its stock price, closing at 44.04 yuan per share on its debut [2] - Guoliang New Materials, a leader in refractory materials, had a first-day stock price increase of 160.78%, closing at 28.06 yuan per share [3] Group 2: Investor Participation - Investor enthusiasm for new stock offerings remains high, with over 800 billion yuan frozen for the three new listings, resulting in low allocation rates of 0.02%-0.03% [4] - Kema Materials attracted 855.76 billion yuan in frozen funds with a subscription rate of 0.026%, while Aisheren had 878.92 billion yuan with a rate of 0.028%, and Guoliang New Materials saw 828.08 billion yuan with a rate of 0.021% [4] - The upcoming IPOs of Nongda Technology and Medela are expected to draw significant investment, with Nongda Technology's recent offering seeing 9.29 billion yuan frozen and a subscription multiple of 2582.89 times [4] Group 3: Regulatory Environment - The frequency of IPO review meetings at the BSE has significantly increased since Q4 2025, focusing on nurturing specialized and innovative hard-tech enterprises [4] - In the week of January 19-23, the BSE's listing committee held three review meetings, successfully approving three companies: Bairuiji, Mifutech, and Toptech [4] - The enhanced review efficiency and improved market ecology position the BSE as a core channel for innovative enterprises to connect with capital markets [4]

Core Insights - The Beijing Stock Exchange (BSE) is becoming a significant platform for innovative small and medium-sized enterprises, with 290 listed companies and a total market capitalization nearing 1 trillion yuan as of January 23, 2026 [1] - The IPO review process on the BSE is maintaining a high frequency, with expectations for continued rapid issuance of new listings due to ongoing market reforms [1] Group 1: Recent Listings - Three companies have recently gone public on the BSE: Kema Materials, Aisheren, and Guoliang New Materials, all of which have shown strong stock performance post-listing [1][2] - Kema Materials, listed on January 16, 2026, saw its stock price surge by 585% at one point, closing at 54.95 yuan per share, a 371.27% increase from its issue price [1] - Aisheren, which focuses on medical health products, listed on January 21, 2026, and its stock rose by 175.59% to close at 44.04 yuan per share [2] - Guoliang New Materials, listed on January 22, 2026, experienced a stock price increase of 160.78%, closing at 28.06 yuan per share [2] Group 2: Investor Participation - Investor enthusiasm for new stock offerings is high, with over 800 billion yuan in frozen funds for the three new listings, resulting in low allocation rates of 0.02% to 0.03% [3] - Kema Materials attracted 855.77 billion yuan in frozen funds with a subscription rate of 0.026%, while Aisheren had 878.92 billion yuan with a rate of 0.028%, and Guoliang New Materials saw 828.08 billion yuan with a rate of 0.021% [3] - The upcoming IPOs of Nongda Technology and Medela are expected to draw even more investment, with Nongda Technology's recent offering resulting in 9.29 billion yuan in frozen funds and a subscription multiple of 2582.89 times [3] Group 3: Regulatory Environment - The frequency of IPO review meetings on the BSE has significantly increased since Q4 2025, focusing on nurturing specialized and innovative technology enterprises [3] - In the week of January 19-23, 2026, the BSE's listing committee held three review meetings, successfully approving three companies: Bairuiji, Mifutech, and Toptech [3] - The enhanced review efficiency and improved market ecosystem position the BSE as a key channel for innovative enterprises to connect with capital markets [3]

2026 年 01 月 25 日 北交所定期报告 新股审核及上市提速，关注专精特新 小巨人及业绩超预期企业 本周市场回顾： 本周上证指数上涨 0.52%，北证 A 股指数上涨 2.33%，跑赢上证综指 1.81pct，北证 50 指数上涨 2.4%,跑赢上证综指 1.89pct，创业板指 数上涨 1.23%，科创板指数上涨 1.5%； 流动性方面，本周北证 A 股总成交额为 1320.1 亿元，北证 50 总成交 额 427.7 亿元，占北证 A 股总成交额的 32.4%，环比-0.62pct。北证 A 股日均成交额 264.02 亿元，环比-34.3%，区间日均换手率为 4.27%， 较上一区间下降 2.11pct； 估值方面，截至 2026 年 1 月 23 日，北证 A 股市盈率中位数为 45.61X； 同期科创板、创业板 PE 中位数分别为 36.5 倍、37.2 倍。 个股表现&新股上市情况： 截至 2026 年 1 月 23 日，北交所上市公司总数为 290 家，较上周增加 2 家，涨幅靠前的分别为:华维设计、连城数控、亿能电力、欧普泰、 美邦科技、流金科技、特瑞斯、天力复合、能之光、民士达；跌幅 ...

Group 1 - The core viewpoint of the report highlights the resurgence of the commercial aerospace sector driven by the space photovoltaic theme, with significant stock performance from companies like Liancheng CNC and Optec [11][12] - The North Exchange 50 index increased by 2.6%, while trading volume decreased, indicating a shift of funds from large-cap indices to small-cap stocks [6][16] - The report notes that public fund disclosures for Q4 2025 show a decrease in the market value of heavy holdings in the North Exchange, suggesting a trend of profit-taking among investors [12] Group 2 - The report emphasizes the importance of Elon Musk's statements at the Davos Forum, which have activated interest in the space photovoltaic sector, with a focus on companies like Liancheng CNC [13] - Investment analysis suggests maintaining high market activity before the Spring Festival, with recommendations to invest in undervalued stocks and sectors with good growth prospects, such as semiconductors and AI computing [13] - The report details the performance of new stocks listed on the North Exchange, including Aisheren and Guoliang New Materials, which saw significant first-day price increases [28][31] Group 3 - The report provides a detailed analysis of stock performance, noting that 218 stocks rose while 71 fell, with a rise-to-fall ratio of 3.07, indicating a strong market sentiment [38] - It highlights the top-performing stocks of the week, including Huawai Design and Liancheng CNC, which experienced substantial gains [40] - The report also discusses the trading dynamics, with a notable decrease in trading volume and turnover rates for certain stocks, reflecting market volatility [43][26] Group 4 - The report outlines the new listings and financing activities in the New Third Board, indicating a healthy pipeline of new companies entering the market [49] - It mentions the completion of financing for several companies, showcasing the ongoing interest and investment in emerging sectors [50][51] - The report concludes with a summary of the current state of the New Third Board, including the number of companies listed and the financing amounts raised [49][50]

美德乐此次新股申购的冻结资金量，创下北交所开市以来的新高。 另据Wind统计，除上述2股外，还有6只北交所个股打新冻结资金超过8000亿元，涉及锦华新材、国亮 新材、爱舍伦等。 | 证券代码 | 证券简称 | 首发上市日期 | 网上发行中签率 网上冻结资金 [車位] % | [单位] 亿元 | 首发价格 [単位] 元 | | --- | --- | --- | --- | --- | --- | | 920159.BJ 农大科技 | | 2026-01-28 | 0.04 | 9,298.39 | 25.00 | | 920076.BJ 国亮新材 | | 2026-01-22 | 0.02 | 8,280.77 | 10.76 | | 920050.BJ 爱舍伦 | | 2026-01-21 | 0.03 | 8,789.21 | 15.98 | | 920086.BJ 科马材料 | | 2026-01-16 | 0.03 | 8,557.65 | 11.66 | 值得一提的是，2026年以来，北交所已上市的3只新股，打新冻资规模均维持在较高水平。 按照上市日期，3只个股科马材料、爱舍伦、国亮新材，分别于1月 ...

Group 1: Market Overview - The National Medical Insurance Administration is advancing the "going out" strategy for Chinese pharmaceuticals and medical devices, with a focus on building a multi-level support network for international procurement by 2026[1] - In 2025, China is expected to approve 76 innovative drugs, with over 150 transactions amounting to more than $130 billion[1] - By 2024, China's medical device exports are projected to account for 8.17% of the global market, maintaining the fourth position worldwide[1] Group 2: Financial Performance - Revenue for medical device manufacturing companies in China is expected to reach 1.42 trillion yuan in 2025, reflecting a year-on-year growth of 5%[1] - As of October 2025, the number of medical device manufacturers in China reached 33,300, an increase of 576 from the end of 2024[1] - The number of effective invention patents in the medical device sector is projected to reach 50,525 by 2024, a year-on-year increase of 21.63%[1] Group 3: Export and Import Trends - From January to October 2025, the export value of IVD instruments, diagnostic equipment, and dental materials was 30.8 billion yuan, 67.4 billion yuan, and 9.3 billion yuan respectively, with year-on-year growth rates of 11.16%, 9.43%, and 12.15%[1] - IVD reagent imports saw a year-on-year decline of 22.89%, indicating reduced reliance on imports, while high-end diagnostic equipment still shows demand[1] Group 4: Stock Market Performance - The North Exchange's pharmaceutical and biological sector saw a weekly increase of 1.18%, with medical devices rising by 1.83%[2] - 85.71% of pharmaceutical and biological stocks on the North Exchange experienced price increases this week[2]

Group 1 - The report highlights the strategic support from the National Medical Insurance Administration for the "going out" strategy of Chinese pharmaceuticals and medical devices, indicating a systematic empowerment phase for international expansion [10][11][12] - By 2025, China is expected to approve 76 innovative drugs, with over 150 transactions for external authorization, amounting to more than 130 billion USD, showcasing the global appeal of Chinese pharmaceutical innovations [11][12] - The medical equipment export market is projected to cover over 190 countries and regions, with a global market share of 8.17% in 2024, ranking China fourth globally [21][31] Group 2 - The report notes that the revenue of medical device manufacturing companies in China is expected to reach 1.42 trillion CNY in 2025, reflecting a year-on-year growth of 5% [16][19] - As of October 2025, the number of medical device manufacturers in China is projected to reach 33,300, indicating a continuous increase in production capacity [19][20] - The number of effective invention patents in the medical device sector is expected to reach 50,525 in 2024, representing a year-on-year growth of 21.63%, which supports innovation in the industry [20][24] Group 3 - The report identifies eight medical device and biopharmaceutical companies listed on the Beijing Stock Exchange, including Danaher Biologics, Beikang, and others, highlighting their market presence [34][30] - Among the 101 companies listed on the New Third Board related to medical devices, 31 are recognized as national-level specialized and innovative "little giant" enterprises, with six expected to achieve a net profit exceeding 70 million CNY in 2024 [34][35] - The report mentions that 14 companies in the medical and biological field are currently awaiting approval on the Beijing Stock Exchange, with an average revenue of 438 million CNY in 2024 [48][51]

Group 1 - The core viewpoint of the article highlights the recent trends in domestic investment and financing activities, indicating a decrease in the number of financing events compared to the previous week [7][5]. - A total of 62 financing events were disclosed in the domestic primary market this week, with a total financing scale of 2.382 billion RMB, averaging 104 million RMB per event [7]. - The most active sectors in terms of financing events were intelligent manufacturing, artificial intelligence, and healthcare, with 15, 14, and 8 events respectively [8]. Group 2 - In terms of disclosed financing amounts, artificial intelligence led with a total financing scale of approximately 1.231 billion RMB, including a notable A-round financing of 450 million RMB by "Zhejiang Renxing," a humanoid robot developer [10]. - The intelligent manufacturing sector followed with a disclosed financing total of 350 million RMB, highlighted by "Minggan Semiconductor," which completed an A-round financing of 110 million RMB [10]. - The geographical distribution of disclosed financing events was primarily concentrated in Jiangsu, Shanghai, and Beijing, with 14, 11, and 9 events respectively [14]. Group 3 - The stage distribution of the disclosed financing events showed that 49 were early-stage, 12 were growth-stage, and 1 was late-stage [18]. - The article also noted significant financing events, including a Pre-A round of 450 million RMB for a humanoid robot developer and several C rounds in the artificial intelligence sector [23]. - The article reported 14 completed merger and acquisition events, with a notable acquisition by Dongyangguang Technology for 28 billion RMB of Qinhuai Data, a data center solutions provider [34].

Group 1 - Jiangsu Aisheren Medical Technology Group Co., Ltd. officially listed on the Beijing Stock Exchange on January 21, 2026, marking it as the first A-share listed company in Jiangsu Province and the first company from Xiangcheng to be listed on the Beijing Stock Exchange [1] - The IPO involved the issuance of 16.9198 million shares at a price of 15.98 yuan per share, raising a total of 270 million yuan, primarily for the construction of the Kaipule Public Health Medical Supplies Industrial Park [1] - Aisheren specializes in disposable medical consumables and ranks among the top ten exporters of padding medical dressings in China, supported by nearly 80 patents and a network of nine factories globally, exporting to over 50 countries [1] Group 2 - Xiangcheng District emphasizes the importance of corporate listings and actively supports companies in their listing efforts, providing real-time solutions and policies to meet corporate needs [1] - The district has implemented the "Seedling Plan" and established a "five-tier" cultivation model to enhance the connection between enterprises and the capital market, holding various meetings to coordinate essential resources for companies [1] - As of now, there are 20 listed companies in the district, with a total market value of approximately 130 billion yuan [1]

来源：智通财经 智通财经记者 | 陈靖 在A股、H股IPO市场持续升温的大背景下，北京证券交易所（下称"北交所"）正以显著提速的审核发行节奏崭露头角。 近期北交所呈现"一周三审、两股上市、两股打新"的密集态势，业内人士一致认为，叠加新股市场持续释放的赚钱效 应，标志着北交所高质量扩容进入新阶段，成为资本市场服务创新型中小企业的核心阵地之一。 北交所IPO审核的"加速跑"态势自2025年四季度已悄然显现，进入2026年开年更是火力全开。Wind数据显示，2025年11 月至12月，北交所密集审议25家企业IPO申请，23家成功过会，基本接近全年一半，过会率维持高位。 从全年受理情况来看，北交所市场已整体呈现出高质高量的扩容发展态势。东北证券对智通财经表示，"2025年北交所 新增受理企业数量达176家，实现同比大幅增长。这批受理企业共涉及35个细分行业，布局以机械、汽车零配件、化 工、电子设备等领域为主，且全面覆盖北交所上市的全部标准。企业层面，整体营收规模与盈利能力均实现同比显著提 升；地域分布上，受理企业主要集中在广东、江苏、浙江等经济发达地区。" 今年这一节奏持续强化，截至1月23日，月内已召开6场上市委 ...